Our partnership is growing
OUR PARTNERSHIP
Together, our organizations are uniquely positioned for this work and will recruit additional partners as needs arise.
The COVID-19 Vaccine Equity Project is a joint initiative of Sabin, Dalberg, and JSI, with support from Skoll Foundation and through close collaboration with ACT-A. Through country engagement and participation in regional and global working groups, we will continue to identify needs and respond with additional expertise and capacity. We welcome best-in-class experts to join the COVID-19 Vaccine Equity Project.
The Sabin Vaccine Institute is a leading advocate for expanding vaccine access and uptake globally, advancing vaccine research and development, and amplifying vaccine knowledge and innovation. Sabin’s team brings a depth of expertise in promoting equitable vaccine access for infectious diseases, global immunization policy and programming, vaccination acceptance and demand, as well as a platform to engage immunization professionals globally through the Boost Community.
JSI Research & Training Institute, Inc. (JSI) is composed of public health care and health systems consultants and researchers operating in 43 countries and driven by a passion to improve health services and outcomes for all. Through tailored technical assistance and country engagement, JSI assists states and countries to introduce new vaccines as well as strengthen and expand existing routine immunization programs.
Dalberg works to build a more inclusive and sustainable world where all people, everywhere, can reach their fullest potential. The firm partners with and serves communities, governments, and companies providing an innovative mix of services – advisory, investment, research, analytics, and design – to create impact at scale, both within and outside the health sector, including in the COVID context.
The Skoll Foundation is an anchor funder in the COVID-19 Vaccine Equity Project, supporting the work on phases 1 and 2 of the initiative. The Skoll Foundation has been active in funding the COVID-19 response, with an expressed total commitment to pandemic-related work that may reach $500 million across a range of initiatives.
Our partnership is growing. Through country engagement, we will continue to identify needs and respond with additional expertise and capacity. We welcome best-in-class experts to join the COVID-19 Vaccine Equity Project.
The COVID-19 Vaccine Equity Project is a partnership across Sabin, Dalberg, and JSI and coordinated through a small management office, led by Trevor Zimmer.